

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

- Data collection
- Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	The chosen sample size are based on the numbers used for previous publications, which is most optimal to generate statistically significant results.
Data exclusions	No data were excluded from the analysis.
Replication	For in vitro study, at least 2 independent sets were performed, and all findings were reliably reproduced.
Randomization	No randomization was applied in this study
Blinding	In vivo experiments using mice were performed in a blinded fashion such that the people conducting and/or analyzing the assay were not aware of treatment groups or mice gene until data gathering were complete.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involvement in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data

Methods

n/a	Involvement in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

Antibodies

Antibodies used

anti-mouse F4/80 eBioscience 14-4801
 anti-Desmin R&D systems AF6844
 anti-phospho-p65 Cell signaling technology 3033
 anti-NF-kappaB p65 Cell signaling technology 8242
 anti-mouse CD11B-APC eBioscience 17-0112
 anti-mouse F4/80-PE Cy7 eBioscience 25-4801
 anti-mouse F4/80 eBioscience 14-4801-82
 anti-AQP3 Millipore AB3276
 goat anti-rabbit IgG-FITC sigma F9887
 phospho-H2A.X Cell signaling technology 9718
 anti-TNF-alpha fluoro 450 eBioscience 48-7321
 anti-CD45.1 PE-Cy7 Invitrogen 25-0453-82
 anti-CD45.2 APC eBioscience 17-0454-81
 anti-Na-K-ATPase Millipore 05-369
 anti-smooth muscle actin DAKO M0851
 anti-CD68 Proteintech 66231-2-Ig

Validation

Antibody specificity was assessed by the manufacturer. All antibodies were titrated prior to use.

Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)

CHO-K1 cells (Riken BRC cell bank, JAPAN)
 HaCaT cells (from Dr Fusenig, German Cancer Research Center, Heidelberg, Germany)

Authentication

All cell lines were authenticated using the short tandem repeat profiling.

Mycoplasma contamination	All cell lines were periodically tested for mycoplasma contamination using MycoAlert™ mycoplasma detection kit (Lonza). None of the cell lines were contaminated.
Commonly misidentified lines (See ICLAC register)	No commonly misidentified cell lines were used in this study.

Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

Laboratory animals	C57BL/6 mice , 7-10 weeks old, AQP3 knockout mice, 7-10 weeks old
Wild animals	The study did not involve wild animals.
Field-collected samples	The study did not involve samples collected from the field.
Ethics oversight	All research involving animal experiments were approved by the Committee on Animal Research of Keio University

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Flow Cytometry

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation	Livers were perfused with liver perfusion medium (Invitrogen) and then liver digest medium (Invitrogen). For Fig. 1d, cell suspension were stained with anti-F4/80 and anti-CD11B. For Fig 2F, the dispersed cells were centrifuged (50x g, 1 minute) to remove hepatocytes as pellets. The recovered nonparenchymal cells containing macrophages were stained with anti-F4/80 and anti-CD11B, and incubated by Fixation/permeabilization solution (BD bioscience). Cells were incubated with BD perm/wash buffer (BD bioscience), following stained with anti-TNF-alpha.
Instrument	Gallios (Beckman)
Software	FlowJo
Cell population abundance	Approximately 10 % of cells were determined for each.
Gating strategy	For Fig. 2f, CD11B+ F4/80+ cells were collected.

- Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.